Masaru Matsuda sells ARQT shares under Rule 144

Masaru Matsuda reported Rule 144 sale notices for Arcutis Biotherapeutics common stock.

Rhea-AI Filing Summary

Masaru Matsuda reported Rule 144 sale notices for Arcutis Biotherapeutics common stock. The filing lists sales of 40,638, 3,325 and 1,675 shares in the past three months, and separately lists restricted stock vesting of 6,746, 3,325 and 1,987 shares on the dates shown.

The broker listed is Merrill Lynch and the security trades on NASDAQ. The filing records transaction dates including 02/02/2026, 02/27/2026 and 12/01/2025.

Insights

Insider Transactions Analyst

Rule 144 sale notices from a single reporting person are routine disclosures of secondary market activity.

The excerpt lists three sale entries by Masaru Matsuda totaling the individual amounts 40,638, 3,325 and 1,675 shares with transaction dates in 12/01/2025, 02/02/2026 and 02/27/2026

Separately, the filing shows restricted stock vesting events of 6,746, 3,325 and 1,987 shares on their listed dates; timing and disposition of vested shares depend on the holder's decisions and are not detailed here.

Corporate Governance Specialist

Broker and trading venue are identified; the filing documents executed sales rather than an issuer offering.

The broker is listed as Merrill Lynch and the security is on NASDAQ, indicating standard market channels for the disclosed transactions. The entries are transactional records, not an issuance or shelf registration.

Cash‑flow treatment to the issuer is not included in the excerpt; subsequent filings would state any additional context if required.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What Rule 144 sales did Masaru Matsuda report for ARQT?

Masaru Matsuda reported sales of 40,638, 3,325 and 1,675 ARQT shares. The filing lists those three sale transactions with dates including 02/02/2026 and 02/27/2026.

Does the Form 144 show restricted stock vesting for ARQT?

Yes. The filing lists restricted stock vesting of 6,746, 3,325 and 1,987 common shares on the specific vesting dates shown in the excerpt, tied to the holder rather than an issuer sale.

Which broker and exchange are shown in the Form 144 for ARQT?

The broker is listed as Merrill Lynch with an address on Lyra Drive, Columbus, OH, and the security is identified as trading on NASDAQ in the excerpt provided.

Are proceeds to the company reported in this Form 144 for ARQT?

No. The excerpt documents secondary sales and vesting events; it does not state that any proceeds were received by the issuer or provide use‑of‑proceeds information in the provided text.

What dates are tied to the reported transactions in the ARQT filing?

Transaction and vesting dates shown include 12/01/2025, 02/02/2026, 02/27/2026, and vesting entries on 03/01/2026 and 03/02/2025 as listed in the excerpt.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/02/2026 - 06:48 PM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001798679
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	ARCUTIS BIOTHERAPEUTICS, INC.
SEC File Number	001-39186
Address of Issuer	3027 Townsgate Road Suite 300 Westlake Village CALIFORNIA 91361
Phone	805418-5006
Name of Person for Whose Account the Securities are To Be Sold	Masaru Matsuda
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 8890 Lyra Drive 5th Floor Columbus OH 43240	12058	313878	124033382	03/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/01/2026	Restricted Stock Vesting	Arcutis Biotherapeutics			6746	03/01/2026	NA
Common	02/27/2025	Restricted Stock Vesting	Arcutis Biotherapeutics			3325	02/27/2025	NA
Common	03/02/2025	Restricted Stock Vesting	Arcutis Biotherapeutics			1987	03/02/2025	NA

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Masaru Matsuda 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	Common	12/01/2025	1675	50041
Masaru Matsuda 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	Common	02/02/2026	40638	1027275
Masaru Matsuda 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	Common	02/27/2026	3325	92933.75

144: Remarks and Signature

Remarks	5312 shares were sold pursuant to10b5-1 plan
Date of Notice	03/02/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/06/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Masaru Matsuda
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)